MCID: LMT001
MIFTS: 46

Limited Scleroderma malady

Categories: Rare diseases, Nephrological diseases, Respiratory diseases, Bone diseases, Skin diseases, Immune diseases

Aliases & Classifications for Limited Scleroderma

About this section

Aliases & Descriptions for Limited Scleroderma:

Name: Limited Scleroderma 11 13
Limited Cutaneous Systemic Sclerosis 11 48 54
Systemic Sclerosis Sine Scleroderma 48 54 68
Limited Cutaneous Systemic Scleroderma 48 54
Limited Systemic Sclerosis 48 54
 
Scleroderma, Limited 39 68
Progressive Systemic Sclerosis Sine Scleroderma 48
Systemic Sclerosis, Limited 11
Scleroderma, Sine 48
Crest Syndrome 68

Characteristics:

Orphanet epidemiological data:

54
limited cutaneous systemic sclerosis:
Inheritance: Multigenic/multifactorial,Not applicable; Age of onset: Adult; Age of death: adult
systemic sclerosis sine scleroderma:
Inheritance: Not applicable; Age of onset: Adult

Classifications:



External Ids:

Disease Ontology11 DOID:1577
MeSH39 D045745
ICD10 via Orphanet31 M34.1, M34.0

Summaries for Limited Scleroderma

About this section
NIH Rare Diseases:48 Limited cutaneous systemic sclerosis is a subtype of systemic sclerosis characterized by the association of raynaud's phenomenon and skin fibrosis on the hands, face, feet and forearms. the exact cause of limited cutaneous systemic sclerosis is unknown, but likely originates from an autoimmune reaction which leads to overproduction of collagen. in some cases, the condition is associated with exposure to certain chemicals. management is aimed at treating the symptoms present in each affected individual.  last updated: 5/27/2015

MalaCards based summary: Limited Scleroderma, also known as limited cutaneous systemic sclerosis, is related to diffuse scleroderma and crest syndrome, and has symptoms including Array, Array and Array. An important gene associated with Limited Scleroderma is HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1), and among its related pathways are IL12-mediated signaling events and IL12 signaling mediated by STAT4. Affiliated tissues include skin, bone and thyroid.

Related Diseases for Limited Scleroderma

About this section

Diseases related to Limited Scleroderma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 45)
idRelated DiseaseScoreTop Affiliating Genes
1diffuse scleroderma27.0ATRAID, CAV1, CCR6, CENPA, CENPB, CENPC
2crest syndrome11.2
3reynolds syndrome11.0
4systemic scleroderma11.0
5non-amyloid monoclonal immunoglobulin deposition disease10.2HLA-DRB1, IL2RA
6cerebral sarcoidosis10.2HLA-DRB1, IL2, IL2RA
7renal agenesis meningomyelocele mullerian defect10.2HLA-DRB1, IL2
8heart conduction disease10.2HLA-DRB1, IL2, IL2RA
9caplan's syndrome10.2HLA-DRB1, IL2
10agraphia10.2CENPB, CTGF, TOP1
11rheumatic fever10.1MNDA, PYHIN1, TOP1
12respiratory system disease10.1CENPA, CENPB, HLA-DRB1, IL2RA
13erythromelalgia10.0TOP1, UBTF
14herpes simplex10.0CENPB, CTGF, SNRNP70, TOP1
15clivus meningioma10.0CENPB, CENPC, HLA-DRB1, SNRNP70, TOP1
16dihydroxyadeninuria9.9CAV1, CCR6, CTGF, HLA-DRB1, IFI16, IRF5
17testicular lymphoma9.9CENPA, CENPB, CTGF, SNRNP70, TOP1
18cousin syndrome9.9HLA-DRB1, IL2, IL2RA, IRF5, SNRNP70
19wolff-parkinson-white syndrome9.9
20dermatomyositis9.9
21pulmonary hypertension9.8
22rheumatoid arthritis9.7
23arthritis9.7
24nephrotic syndrome9.7
25glomerulonephritis9.7
26primary biliary cirrhosis9.7
27thyroiditis9.7
28vasculitis9.7
29renal cell carcinoma9.5
30arteriovenous fistula9.5
31myasthenia gravis9.5
32osteonecrosis9.5
33pemphigus foliaceus9.5
34thrombotic thrombocytopenic purpura9.5
35esophagitis9.5
36sjogren's syndrome9.5
37calcinosis9.5
38melanoma9.5
39interstitial lung disease9.5
40purpura9.5
41pneumonia9.5
42lung disease9.5
43pemphigus9.5
44fibrillary glomerulonephritis9.5
45pauci-immune glomerulonephritis9.5

Graphical network of the top 20 diseases related to Limited Scleroderma:



Diseases related to limited scleroderma

Symptoms & Phenotypes for Limited Scleroderma

About this section

Human phenotypes related to Limited Scleroderma:

 54 64 (show all 17)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 abnormality of the skin54 Very frequent (99-80%)
2 abnormality of skin pigmentation54 Very frequent (99-80%)
3 hypopigmented skin patches64 54 Very frequent (99-80%) HP:0001053
4 dysphagia64 54 Frequent (79-30%) HP:0002015
5 nausea and vomiting64 54 Frequent (79-30%) HP:0002017
6 gastroesophageal reflux64 54 Frequent (79-30%) HP:0002020
7 pulmonary hypertension54 Occasional (29-5%)
8 pulmonary fibrosis64 54 Occasional (29-5%) HP:0002206
9 autoimmunity64 54 Very frequent (99-80%) HP:0002960
10 contractures involving the joints of the feet64 54 Occasional (29-5%) HP:0008366
11 joint contracture of the hand64 54 Occasional (29-5%) HP:0009473
12 mucosal telangiectasiae64 54 Frequent (79-30%) HP:0100579
13 teleangiectasia of the skin54 Frequent (79-30%)
14 narrow foramen obturatorium64 54 Very frequent (99-80%) HP:0100958
15 skin ulcer64 54 Frequent (79-30%) HP:0200042
16 pulmonary arterial hypertension64 HP:0002092
17 telangiectasia of the skin64 HP:0100585

Drugs & Therapeutics for Limited Scleroderma

About this section

Drugs for Limited Scleroderma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 94)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Nitroglycerinapproved, investigationalPhase 315655-63-04510
Synonyms:
1,2,3-Propanetrioltrinitrate
1,2,3-Propanetriyl nitrate
100292-13-5
105469-31-6
55-63-0
80066-48-4
8013-23-8
9010-02-0
AC1L1IBV
Adesitrin
Aldonitrin
Angibid
Angiolingual
Angiplex
Anglix
Angonist
Angorin
Anogesic
Aquo-Trimitrosan
BIDD:GT0142
BRN 1802063
Blasting gelatin
Blasting oil
Buccal
Buccard
C07455
C3H5N3O9
CCRIS 4089
CHEBI:28787
CHEMBL730
CID4510
CPD-143
Cardabid
Cardamist
Cardinit
Cardiodisco
Cellegesic
Chitamite
Colenitral
Cordipatch
Corditrine
Coro-Nitro
D00515
D005996
DB00727
Dauxona
Deponit
Deponit 5
Deponit TTS 10
Deponit TTS 5
Deponit-5
Diafusor
Discotrine
Dynamite
EINECS 200-240-8
Epinitril
GTN
GTN-Pohl
Gepan Nitroglicerin
Gilucor nitro
Gilustenon
Glonoin
Glycerin trinitrate
Glycerine trinitrate
Glycerintrinitrate
Glycerol trinitrate
Glycerol, nitric acid triester
Glyceroli trinitratis
Glyceroltrinitraat
Glyceroltrinitrat
Glyceryl
Glyceryl nitrate
Glyceryl trinitrate
Glycerylnitrat
Glytrin
HMS2094M15
HSDB 30
Herwicard
Herzer
IMX-150
Klavikordal
LS-7741
Lenitral
Lentonitrina
MED-2002
MQX-503
Mi-Trates
Millisrol
Minitram
Minitran
Minitran (TN)
Minitro
Mionitrat
Myocon
Myoglycerin
Myovin
NG
NITRO IV
NK-843
NTG
Natispray
Neos nitro OPT
Niglin
Niglycon
Niong
Niong Retard
Nirmin
Nit-Ret
Nitora
Nitradisc
Nitradisc Pad
Nitradisc TTS
Nitrangin
Nitrek
Nitriderm
Nitriderm TTS
Nitrine-TDC
Nitro Bid
Nitro Dur
Nitro Dur TTS
Nitro Mack Retard
Nitro Retard
Nitro Rorer
Nitro-Bid
Nitro-Dur 10
Nitro-Dur 5
Nitro-Gesanit Retard
Nitro-M-Bid
Nitro-Mack Retard
Nitro-Par
Nitro-Pflaster
Nitro-Span
Nitro-Time
Nitro-bid (TN)
Nitro-dur
Nitro-dur (TN)
Nitro-lent
NitroBid
NitroCor
 
NitroDur
NitroMist
NitroQuick
NitroQuik
Nitroard
Nitrobaat
Nitrobid Oint
Nitrobukal
Nitrocap
NitrocapT.D
NitrocapT.D.
Nitrocard
Nitrocerin
Nitrocine
Nitrocine 5
Nitroclyn
Nitrocontin
Nitrocontin Continus
Nitrocot
Nitroderm
Nitroderm TTS
Nitroderm TTS Ext
Nitroderm TTS-5
Nitrodisc
Nitrodyl
Nitrodyl TTS
Nitrogard
Nitrogard-SR
Nitroglicerina
Nitrogliceryna
Nitroglin
Nitroglycerin
Nitroglycerin (NG)
Nitroglycerin ointment
Nitroglycerin-ACC
Nitroglycerine
Nitroglycerol
Nitroglyn
Nitroject
Nitrol Ointment
Nitrolan
Nitroletten
Nitrolin
Nitrolingual
Nitrolingual Spray
Nitrolowe
Nitromack Retard
Nitromed
Nitromel
Nitromex
Nitromint
Nitromint Aerosol
Nitromint Retard
Nitromist
Nitromist (TN)
Nitronal Aqueous
Nitronet
Nitrong
Nitrong Retard
Nitrong parenteral
Nitrong-SR
Nitropatch
Nitropen
Nitropercuten
Nitroperlinit
Nitroplast
Nitroprol
Nitropront
Nitroprontan
Nitrorectal
Nitroretard
Nitrorex
Nitrospan
Nitrostabilin
Nitrostat
Nitrovis
Nitrozell retard
Nysconitrine
Percutol
Percutol Oint
Percutol Oint.
Perganit
Perglottal
Perlinganit
Plastranit
Polnitrin
Propane-1,2,3-triyl trinitrate
RCRA waste no. P081
Ratiopharm
Rectogesic
SDM No. 17
SK-106N
SK-866
SK-878
Soup
Spirit of glonoin
Susadrin
Suscard
Sustac
Sustak
Sustonit
TNG
Temponitrin
Top-Nitro
Transderm Nitro
Transderm nitro
Transderm-N TTS
Transderm-Nitro TTS
Transderm-nitro
Transderm-nitro (TN)
Transiderm-nitro
Tridil
Tridil sublin
Trinalgon
Trinipatch
Triniplas
Trinitrate, Glyceryl
Trinitrin
Trinitrin Tablets
Trinitrina Erba
Trinitrine
Trinitroglycerin
Trinitroglycerol
Trinitrol
Trinitrolong
Trinitron
Trinitrosan
Turicard
UN0143
UN0144
UN1204
UN3064
UN3319
UNII-G59M7S0WS3
Vascana
Vasoglyn
Vasolator
Vernies
Willong
c0061
nitroglycerin
2
Lidocaineapproved, vet_approvedPhase 2, Phase 31317137-58-63676
Synonyms:
.alpha.-(Diethylamino)-2,6-acetoxylidide
.alpha.-Diethylamino-2,6-dimethylacetanilide
.alpha.-Diethylaminoaceto-2,6-xylidide
.omega.-Diethylamino-2,6-dimethylacetanilide
137-58-6
2-(Diethylamino)-2',6'-acetoxylidide
2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide
2-Diethylamino-N-(2,6-dimethyl-phenyl)-acetamide
2-Diethylamino-N-(2,6-dimethylphenyl)acetamide
4-12-00-02538 (Beilstein Handbook Reference)
6108-05-0 (MONOHYDROCHLORIDE MONOHYDRATE))
6108-05-0 (mono-hydrochloride, mono-hydrate)
73-78-9 (mono-hydrochloride)
AB00053581
AC-10282
AC1L1GGQ
AC1Q2Z7J
AKOS001026768
ARONIS23855
After Burn Double Strength Gel
After Burn Double Strength Spray
After Burn Gel
After Burn Spray
Alphacaine
Anestacon
Anestacon Jelly
BIDD:GT0342
BPBio1_000197
BRD-K52662033-001-02-6
BRD-K52662033-003-05-5
BRN 2215784
BSPBio_000179
BSPBio_001359
BSPBio_003004
Bio-0767
Bio1_000379
Bio1_000868
Bio1_001357
Bio2_000079
Bio2_000559
C07073
C14H22N2O
CAS-73-78-9
CDS1_000283
CHEBI:6456
CHEMBL79
CID3676
CPD000058189
Cappicaine
Cito optadren
Cuivasil
D00358
DB00281
Dalcaine
Dentipatch
Dentipatch (TN)
DermaFlex
Diethylaminoaceto-2,6-xylidide
Dilocaine
DivK1c_000174
DivK1c_001323
Duncaine
EINECS 205-302-8
ELA-Max
EMBOLEX
Emla
Emla Cream
Esracaine
FT-0082378
Gravocain
HMS1791D21
HMS1989D21
HMS2051C21
HMS2089E15
HMS548M19
HSDB 3350
I01-2704
IDI1_000174
IDI1_033829
Isicaina
Isicaine
Jetocaine
KBio1_000174
KBio2_000079
KBio2_001598
KBio2_002647
KBio2_004166
KBio2_005215
KBio2_006734
KBio3_000157
KBio3_000158
KBio3_002224
KBioGR_000079
KBioGR_000599
KBioSS_000079
KBioSS_001598
L-Caine
L0156
L1026_SIGMA
L7757_SIGMA
LIDOCAINE (73-58-6 (MONOHYDROCHLORIDE)
LIDOPEN
LQZ
 
LS-805
Lanabiotic
Leostesin
Lida-Mantle
Lidocaina
Lidocaina [INN-Spanish]
Lidocaine (JP15/USP/INN)
Lidocaine (VAN)
Lidocaine Carbonate
Lidocaine Hydrocarbonate
Lidocaine Monohydrochloride
Lidocaine [USAN:INN:JAN]
Lidocainum
Lidocainum [INN-Latin]
Lidocaton
Lidoderm
Lidoject-1
Lidoject-2
Lignocaine
Lignocainum
Lingocaine
Lopac-L-5647
Lopac0_000669
MLS000069724
MLS000758263
MLS001074177
Maricaine
Maybridge1_002571
MolPort-001-783-478
N-(2,6-dimethylphenyl)-N(2),N(2)-diethylglycinamide
N-(2,6-dimethylphenyl)-N~2~,N~2~-diethylglycinamide
NCGC00015611-01
NCGC00015611-02
NCGC00015611-03
NCGC00015611-04
NCGC00015611-14
NCGC00022176-05
NCGC00022176-06
NCGC00022176-07
NCGC00022176-08
NCGC00022176-09
NINDS_000174
NSC 40030
NSC40030
Norwood Sunburn Spray
Octocaine
Octocaine-100
Octocaine-50
Prestwick0_000050
Prestwick1_000050
Prestwick2_000050
Prestwick3_000050
Remicaine
Rocephin Kit
Rucaina
S1357_Selleck
SAM001247018
SMR000058189
SPBio_001525
SPBio_002100
STK552033
Solarcaine
Solarcaine aloe extra burn relief cream
Solcain
Spectrum2_001343
Spectrum3_001392
Spectrum4_000070
Spectrum5_001549
Spectrum_001118
UNII-98PI200987
WLN: 2N2 & 1VMR B1 F1
Xilina
Xilocaina
Xilocaina [Italian]
Xllina
Xycaine
Xylestesin
Xylesthesin
Xylocain
Xylocaine
Xylocaine (TN)
Xylocaine 5% Spinal
Xylocaine CO2
Xylocaine Dental Ointment
Xylocaine Endotracheal
Xylocaine Test Dose
Xylocaine Viscous
Xylocaine-MPF
Xylocaine-MPF with Glucose
Xylocaine-Mpf
Xylocaine-Mpf with Glucose
Xylocard
Xylocitin
Xyloneural (free base)
Xylotox
Zilactin-L
Zingo
alfa-Dietilamino-2,6-dimetilacetanilide
alfa-Dietilamino-2,6-dimetilacetanilide [Italian]
alpha-Diethylamino-2,6-dimethylacetanilide
alpha-diethylamino-2,6-dimethylacetanilide
lidocaine
nchembio.65-comp16
α-diethylamino-2,6-dimethylacetanilide
3
LenograstimapprovedPhase 31220135968-09-1
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
 
Granulocyte colony stimulating factor 3 (CHO cell derived)
Granulocyte colony-stimulating factor lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
4
Cyclophosphamideapproved, investigationalPhase 3, Phase 1293550-18-0, 6055-19-22907
Synonyms:
(+-)-Cyclophosphamide
(-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
ASTA
ASTA B518
Anhydrous cyclophosphamide
Asta B 518
B 518
B-518
BRN 0011744
BSPBio_002099
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
CID2907
CP
CPA
CTX
CY
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
Clafen
Claphene
Cycloblastin
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide anhydrous
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
 
DB00531
DivK1c_000246
EINECS 200-015-4
EU-0100238
Endoxan
Endoxan R
Endoxan-Asta
Endoxana
Endoxanal
Endoxane
Enduxan
Genoxal
HMS2090A12
HSDB 3047
Hexadrin
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
LS-1302
LS-99787
Ledoxina
Lopac-C-0768
Lopac0_000238
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI-C04900
NCI60_002097
NINDS_000246
NSC 26271
NSC-26271
NSC26271
NSC273033
NSC273034
Neosar
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra Waste Number U058
Rcra waste number U058
Revimmune
S1217_Selleck
SK 20501
SPBio_001071
STK177249
STOCK2S-91217
Semdoxan
Sendoxan
Senduxan
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
Spectrum_000858
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
cyclophosphamide
5
Bupivacaineapproved, investigationalPhase 2, Phase 312332180-92-9, 38396-39-32474
Synonyms:
( inverted exclamation markA)-bupivacaine
(+-)-Bupivacaine
(1)-1-Butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide
(RS)-bupivacaine
(±)-bupivacaine
1-Butyl-2',6'-pipecoloxylidide
1-Butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide
1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide
15233-43-9
2180-92-9
38396-39-3
AB00053674
AC-2096
AC1L1DRE
AC1Q5LX4
AH 250
AKOS001637202
AR-1A0242
Anekain
BPBio1_000298
BRD-A01636364-003-05-2
BSPBio_000270
BSPBio_002607
Bio-0886
Bloqueina
Bucaine
Bucaine (TN)
Bupivacaina
Bupivacaina [INN-Spanish]
Bupivacaine (INN)
Bupivacaine Carbonate
Bupivacaine HCL
Bupivacaine HCL KIT
Bupivacaine Monohydrochloride, Monohydrate
Bupivacaine [INN:BAN]
Bupivacainum
Bupivacainum [INN-Latin]
Bupivan
C07529
C18H28N2O
CBupivacaine
CHEBI:3215
CHEMBL1098
CID2474
Carbostesin
D07552
DB00297
DL-Bupivacaine
DUR-843
 
DepoBupivacaine
DivK1c_000758
EINECS 218-553-3
EINECS 253-911-2
HMS2090F12
IDI1_000758
KBio1_000758
KBio2_002004
KBio2_004572
KBio2_007140
KBio3_001827
KBioGR_001516
KBioSS_002004
KST-1A4609
L000695
LAC-43
LS-109841
LS-2222
MLS001361336
Marcaina
Marcaine
Marcaine HCL
Marcaine Spinal
MolPort-004-955-820
NCGC00178579-01
NCGC00178579-02
NINDS_000758
NSC119660
Prestwick0_000305
Prestwick1_000305
Prestwick2_000305
Prestwick3_000305
SMR000058218
SPBio_001558
SPBio_002489
Sensorcaine
Sensorcaine-MPF
Sensorcaine-MPF Spinal
Spectrum2_001589
Spectrum3_000974
Spectrum4_001098
Spectrum5_001483
Spectrum_001524
Transdur-Bupivacaine
UNII-Y8335394RO
Win 11318
Win 11318 HCl
bupivacaine
cBupivacaine
dl-1-Butyl-2',6'-pipecoloxylidide
racemic bupivacaine
6
Glucosamineapproved, NutraceuticalPhase 2, Phase 31913416-24-8439213
Synonyms:
(+)-2-amino-2-deoxy-D-glucopyranose
(2R,3R,4R,5S,6R)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol
(2S,5R)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol
(3R,4R,5S,6R)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol
14257-69-3
2-Amino-2-deoxy-D-Glucose
2-Amino-2-deoxy-D-glucopyranose
2-Amino-2-deoxy-D-glucose
2-Amino-2-deoxy-beta-D-glucopyranose
2-Amino-2-deoxyglucose
2-Aminoglucose
2-Deoxy-2-amino-D-glucose
2-Deoxy-2-aminoglucose
2-amino-2-deoxy-D-glucopyranose
2-amino-2-deoxyglucose
2351-15-7
28905-10-4
2B4D44B2-D5AC-4DA4-9BE6-A4AE9574E4A6
3416-24-8
4-04-00-02017 (Beilstein Handbook Reference)
58-87-7
58267-75-7
6490-70-6
880765-44-6
90-77-7
911653-84-4
AC1L2D1C
AC1L96WB
AC1L9B8P
AC1Q4UBH
BRN 1724602
BSPBio_002086
C00329
C08349
CHEBI:28393
CHEBI:47977
CHEMBL234432
CID18897
CID439213
CID441477
CPD0-1193
Chitosamine
Cosamin
D-(+)-Glucosamine
 
D-Glucosamine
D-glucosamine
D04334
DB01296
DivK1c_000261
EINECS 222-311-2
GCS
Glucosamina
Glucosamina [INN-Spanish]
Glucosamine (USAN/INN)
Glucosamine [USAN:INN]
Glucosaminum
Glucosaminum [INN-Latin]
HMS500N03
HSDB 7469
IDI1_000261
InChI=1/C6H13NO5/c7-3-5(10)4(9)2(1-8)12-6(3)11/h2-6,8-11H,1,7H2/t2-,3-,4-,5-,6-/m1/s1
KBio1_000261
KBio2_001311
KBio2_003879
KBio2_006447
KBio3_001306
KBioGR_000970
KBioSS_001311
LS-71671
MolPort-002-507-091
MolPort-003-944-937
NCGC00164421-01
NCGC00178826-01
NINDS_000261
SPBio_000477
STK801823
Spectrum2_000519
Spectrum3_000443
Spectrum4_000565
Spectrum5_000756
Spectrum_000831
Viartril-S
beta-D-Glucosamine
bmse000247
chitosamine
glucosamine
nchembio.189-comp4
nchembio.2007.41-comp7
nchembio.412-comp5
partially N-deacetylated poly-beta-1,6-N-acetyl-D-glucosamine
7Vasodilator AgentsPhase 33543
8AnestheticsPhase 2, Phase 39596
9Pharmaceutical SolutionsPhase 2, Phase 3, Phase 18192
10Fibrinolytic AgentsPhase 2, Phase 32388
11Diuretics, Potassium SparingPhase 2, Phase 31917
12Central Nervous System DepressantsPhase 2, Phase 313403
13Peripheral Nervous System AgentsPhase 2, Phase 323689
14Sodium Channel BlockersPhase 2, Phase 31593
15AntimetabolitesPhase 2, Phase 312054
16Hypolipidemic AgentsPhase 2, Phase 32785
17Hypoglycemic AgentsPhase 2, Phase 35896
18Glucuronyl glucosamine glycan sulfatePhase 2, Phase 3140
19Lipid Regulating AgentsPhase 2, Phase 32766
20AnticoagulantsPhase 3, Phase 22623
21Calcium, DietaryPhase 35713
22Immunosuppressive AgentsPhase 3, Phase 113086
23Antirheumatic AgentsPhase 3, Phase 2, Phase 110956
24Anti-Arrhythmia AgentsPhase 2, Phase 33093
25Antineoplastic Agents, AlkylatingPhase 3, Phase 14603
26Chelating AgentsPhase 31423
27Alkylating AgentsPhase 3, Phase 14827
28Phosphodiesterase InhibitorsPhase 31289
29Anesthetics, LocalPhase 2, Phase 33492
30Phosphodiesterase 5 InhibitorsPhase 3589
31Sildenafil CitratePhase 3331171599-83-0
32CitrateNutraceuticalPhase 31160
33
Citric Acidnutraceutical, vet_approvedPhase 3116077-92-9311
Synonyms:
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Aciletten
Anhydrous citrate
Anhydrous citric acid
Chemfill
Citraclean
 
Citrate
Citretten
Citric acid
Citro
Citronensäure
E 330
Hydrocerol A
Kyselina citronova
Suby G
Uro-trainer
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
34
Treprostinilapproved, investigationalPhase 29181846-19-754786, 6918140
Synonyms:
((1R,2R,3aS,9aS)-2-hydroxy-1-((3S)-3-hydroxyoctyl)-2,3,3a,4,9,9a-hexahydro-1H-cylopent(b)naphthalen-5-yl)oxy)acetate
(1R,2R,3aS,9aS)-[[2,3,3a,4,9,9a-hexahydro-2-hydroxy- 1-[(3S)-3-hydroxyoctyl]-1H-benz[f]inden-5-yl] oxy]acetic acid
({(1R,2R,3aS,9aS)-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]naphthalen-5-yl}oxy)acetic acid
15 AU81
15AU81
2-[[(1R,2R,3aS,9aS)-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[g]naphthalen-5-yl]oxy]acetic acid
2-[[(1S,2S,3aR,9aR)-2-hydroxy-1-[(3R)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[g]naphthalen-5-yl]oxy]acetic acid
289480-64-4 (Sodium salt)
81846-19-7
AC1L1HPX
AC1OCF2J
CHEBI:50861
CID11246284
CID54786
CID6918140
CID9800580
D06213
DB00374
L001079
 
LRX 15
LS-177654
LS-187014
LS-187645
Remodulin (TN)
Treprostinil
Treprostinil (USAN/INN)
Treprostinil [USAN:INN]
Treprostinil sodium
Treprostinilo
Treprostinilum
U 62840
U-62,840
UNII-RUM6K67ESG
UT-15
Uniprost
Viveta
[[(1R,2R,3aS,9aS)-2-Hydroxy-1-[(3S)-3-hydroxyoctyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]naphtalen-5-yl]oxy]acetic acid
treprostinilo
treprostinilum
35
rituximabapprovedPhase 21692174722-31-710201696
Synonyms:
AntiCD20
IDEC-102
IDEC-C2B8
 
Ig gamma-1 chain C region
MabThera
Mabthera
Rituxan
rituximab
36MitogensPhase 1, Phase 21617
37TezosentanPhase 264
38Antihypertensive AgentsPhase 24207
39ImmunoglobulinsPhase 1, Phase 26394
40Antibodies, MonoclonalPhase 1, Phase 24039
41Protein Kinase InhibitorsPhase 1, Phase 23689
42AntibodiesPhase 1, Phase 26394
43Imatinib MesylatePhase 1, Phase 2600123596
44ifetrobanPhase 25
45Platelet Aggregation InhibitorsPhase 22516
46
Mycophenolic acidapprovedPhase 195224280-93-1446541
Synonyms:
(e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid
Acide mycophenolique
Acido micofenolico
Acidum mycophenolicum
 
Melbex
Micofenolico acido
Mycophenoic acid
Mycophenolate
Mycophenolsäure
Myfortic
47
Interferon beta-1aapproved, investigationalPhase 1200145258-61-36438354
Synonyms:
145258-61-3
Avonex
Avonex (TN)
Belerofon
D04554
 
Fibroblast interferon
IFN-beta
Interferon beta precursor
Interferon beta-1a
Interferon beta-1a (USAN)
Interferon beta-1a (genetical recombination)
Interferon beta-1a (genetical recombination) (JAN)
48
Mycophenolate mofetilapproved, investigationalPhase 1952128794-94-55281078
Synonyms:
115007-34-6
128794-94-5
140401-05-4
2-Morpholinoethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-Morpholinoethyl (e)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
2-morpholin-4-ylethyl (4E)-6-[4-hydroxy-7-methyl-6-(methyloxy)-3-oxo-1,3-dihydro-2-benzofuran-5-yl]-4-methylhex-4-enoate
2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate
4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl -3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (4E)
AC-1562
AC1NQXZW
AC1Q6O6X
AR-1J6939
BB_NC-2566
C07908
C23H31NO7
CHEMBL1456
CID5281078
CellCept
CellCept, RS 61443, TM-MMF, Mycophenolate mofetil
Cellcept
Cellcept (TN)
D00752
DB00688
HMS2090A03
 
HSDB 7436
I01-0898
I06-1947
LS-172272
LS-75572
ME-MPA
MMF
MMF CellCept(TM)
MolPort-000-883-800
Munoloc
Mycophenolate mofetil (JAN/USAN)
Mycophenolic acid morpholinoethyl ester
Mycophenylate mofetil
NCGC00159459-02
NCGC00159459-03
NSC724229
R-99
RS 61443
RS-61443
RS-61443-190
S1501_Selleck
TL8000648
TM-MMF
UNII-9242ECW6R0
ZINC21297660
mycophenolate mofetil
49
FludarabineapprovedPhase 1115421679-14-1, 75607-67-930751
Synonyms:
(2R,3S,4S,5R)-2-(6-amino-2-fluoro-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
(2R,3S,4S,5R)-2-(6-amino-2-fluoropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
2-F-ARAA
2-F-ara-A
2-Fluoro Ara-A
2-Fluoro-9-beta-D-arabinofuranosyladenine
2-fluoro ARA-A
21679-14-1
9-beta-D-Arabinofuranosyl-2-fluoroadenine
9-beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine
9H-Purin-6-amine, 9-beta-D-arabinofuranosyl-2-fluoro- (9CI)
AC1LCW8I
AC1Q51CF
C10H12FN5O4
CCRIS 3382
CHEMBL1568
CID657237
CPD000058874
D07966
EINECS 244-525-5
F-Ara-A
FAMP
FT-0082766
FaraA
Fludara
Fludara, Fludarabine
 
Fludarabina
Fludarabina [Spanish]
Fludarabine
Fludarabine (INN)
Fludarabine 5'-monophosphate
Fludarabine [INN]
Fludarabine monophosphate
Fludarabine phosphate
Fludarabinum
Fludarabinum [Latin]
Fludura
Fluradosa
Fluradosa (TN)
HSDB 6964
I14-4978
LS-15061
MLS000028687
NSC 118218
NSC 118218H
NSC-118218
S1491_Selleck
SAM002548956
SMR000058874
SQ Fludarabine
UNII-1X9VK9O1SC
UNII-P2K93U8740
ZINC04216238
50
DiphenhydramineapprovedPhase 123458-73-1, 147-24-03100
Synonyms:
147-24-0
147-24-0 (HYDROCHLORIDE)
2-(Benzhydryloxy)-N,N-dimethylethylamine
2-(Benzhydryloxy)-N,N-dimethylethylamine, hydrochloride
2-(Diphenylmethoxy)-N,N-dimethylethylamine
2-(diphenylmethoxy)-N,N-dimethylethanamine
2-Diphenylmethoxy-N,N-dimethylethylamine
2-[(diphenylmethyl)oxy]-N,N-dimethylethanamine
2-benzhydryloxy-N,N-dimethylethanamine
2-benzhydryloxyethyl-N,N-dimethylammonium
2-diphenylmethoxy-N,N-demthylethanamine
2PM
58-73-1
88637-37-0 (citrate (1:1))
AB00053460
AC-13704
AC1L1F65
AKOS003658554
Aleryl
Alledryl
Aller-Med
Allerdryl
Allergan
Allergan B
Allergeval
Allergical
Allergina
Allergival
Allermax Caplets
Amidryl
Antistominum
Antitussive
Antomin
Automin
BENADRYL HCl
BIDD:GT0152
BPBio1_000275
BRD-K47278471-003-05-7
BRN 1914136
BSPBio_000249
BSPBio_002219
Bagodryl
Banophen
Banophen Caplets
Baramine
Beldin
Belix
Ben-allergin
Bena
Benachlor
Benadrin
Benadryl
Benadryl (hydrochloride)
Benadryl Allergy
Benapon
Bendylate
Benhydramin
Benodin
Benodine
Benylan
Benylin
Benzantin
Benzantine
Benzhydramine
Benzhydraminum
Benzhydril
Benzhydroamina
Benzhydryl
Betramin
CAS-147-24-0
CCRIS 1959
CHEBI:127629
CHEBI:4636
CHEMBL657
CID3100
CPD-10890
Compoz
D00300
DB01075
DB06975
DIPHENHYDRAMINE, ANTISTOMINUM, BENZHYDRAMINE
Dabylen
Debendrin
Dermistina
Dermodrin
Desentol
Diabenyl
Diabylen
Dibendrin
Dibenil
Dibondrin
Difedryl
Difenhidramina
Difenhidramina [INN-Spanish]
Difenhydramin
Difenhydramine
Difenidramina
Difenidramina [Italian]
Dihidral
Dimedrol
Dimedrol base
Dimedrolum
Dimedryl
Dimehydrinate
Dimethylamine benzhydryl ester
Diphamine
Diphantine
Diphen
 
Diphen Cough
Diphenhist
Diphenhist Captabs
Diphenhydramine
Diphenhydramine (JP15/INN)
Diphenhydramine Base
Diphenhydramine HCl
Diphenhydramine [INN:BAN:JAN]
Diphenhydraminum
Diphenhydraminum [INN-Latin]
Diphenylhydramin
Diphenylhydramine
DivK1c_000368
Dobacen
Dormarex 2
Dryistan
Drylistan
Dylamon
EINECS 200-396-7
Etanautine
FAR 90X2
Genahist
HMS2089E06
HSDB 3066
Histaxin
Hyadrine
Hydramine
Hyrexin
I14-6749
IDI1_000368
Ibiodral
KBio1_000368
KBio2_001460
KBio2_004028
KBio2_006596
KBio3_001439
KBioGR_001099
KBioSS_001460
L000227
LS-68208
Lopac-D-3630
Lopac0_000377
MLS002222276
Medidryl
Mephadryl
MolPort-001-783-508
N,N-Dimethyl-2-(diphenylmethoxy)-ethylamine hydrochloride
N-(2-(Diphenylmethoxy)ethyl)-N,N-dimethylamine
N-(Benzhydryloksy-etylo)dwumetyloamina
N-(Benzhydryloksy-etylo)dwumetyloamina [Polish]
N-[2-(BENZHYDRYLOXY)ETHYL]-N,N-DIMETHYLAMINE
NCGC00015335-01
NCGC00015335-02
NCGC00015335-03
NCGC00015335-10
NCGC00024414-03
NCGC00024414-04
NCI60_002916
NCI60_022782
NINDS_000368
NSC665800
Nausen
Nervine Nighttime Sleep-Aid
Novamina
Nytol Quickcaps
Nytol Quickgels
O-Benzhydryldimethylaminoethanol
O-benzhydryldimethylaminoethanol
Oprea1_254625
PM 255
Prestwick0_000065
Prestwick1_000065
Prestwick2_000065
Prestwick3_000065
Probedryl
Restamin
Restamin (TN)
Rigidil
S51
SMR001307259
SPBio_000961
SPBio_002170
STK103720
STOCK2S-94461
Siladryl
Silphen
Sleep-Eze D
Sleep-Eze D Extra Strength
Spectrum2_000961
Spectrum3_000400
Spectrum4_000520
Spectrum5_000915
Spectrum_000980
Syntedril
Syntodril
TL8003758
Twilite Caplets
UNII-8GTS82S83M
Unisom Sleepgels Maximum Strength
alpha-(2-Dimethylaminoethoxy)diphenylmethane
beta-Dimethylamino-aethyl-benzhydryl-aether
beta-Dimethylamino-aethyl-benzhydryl-aether [German]
beta-Dimethylaminoethanol diphenylmethyl ether
beta-Dimethylaminoethyl benzhydryl ether
beta-Dimethylaminoethylbenzhydrylether
beta-dimethylaminoethyl benzhydryl ether
diphenhydramine
nchembio747-comp18
β-dimethylaminoethyl benzhydryl ether

Interventional clinical trials:

(show all 31)
idNameStatusNCT IDPhase
1A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's PhenomenonUnknown statusNCT00577304Phase 3
2High Dose Cyclophosphamide for Treatment of SclerodermaCompletedNCT00501995Phase 3
3Effect of Sildenafil on the Microcirculatory Blood Flow and Endothelial Progenitor Cells in Systemic SclerosisCompletedNCT01347008Phase 3
4Effectiveness and Safety of Lidocaine for SclerodermaCompletedNCT00740285Phase 2, Phase 3
5Exparel as a Nerve Block for Severe Hand PainTerminatedNCT02374320Phase 2, Phase 3
6AIMSPRO in Established Diffuse Cutaneous Systemic SclerosisUnknown statusNCT00769028Phase 2
7Zibotentan Better Renal Scleroderma Outcome StudyUnknown statusNCT02047708Phase 2
8Imatinib in Systemic SclerosisCompletedNCT00506831Phase 1, Phase 2
9Safety, Tolerability, and Pharmacokinetics of CAT-192 (Human Anti-TGF-Beta1 Monoclonal Antibody) in Patients With Early Stage Diffuse Systemic SclerosisCompletedNCT00043706Phase 1, Phase 2
10Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil DiethanolamineCompletedNCT00775463Phase 2
11Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial HypertensionRecruitingNCT02682511Phase 2
12Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)RecruitingNCT01086540Phase 2
13Efficacy of ORM-12741 for Prevention of Raynaud's PhenomenonTerminatedNCT01315899Phase 2
14Mycophenolate Mofetil in Systemic SclerosisCompletedNCT00433186Phase 1
15Phase I BP Interferon (IFN) Beta-001CompletedNCT02515695Phase 1
16Nonmyeloablative Allo Stem Cell Transplant for Severe Autoimmune DiseasesTerminatedNCT00849745Phase 1
17Transversalis Fascial Plane Nerve Block in Iliac Crest Bone GraftUnknown statusNCT01133730
18Lower Urinary Tract Symptoms in Systemic SclerosisUnknown statusNCT01971294
19Peripheral Muscle Microcirculation and Exercise-induced Blood Flow Distribution in Pulmonary Arterial HypertensionUnknown statusNCT01520493
20A Non-Interventional Pilot Study Assessing Whether Lysyl Oxidase-like 2 (LOXL2) is Present in Subjects With SclerodermaCompletedNCT01881529
21Efficacy of Ambrisentan in Limited Scleroderma Patients in Improving Blood Flow to Hands or FeetCompletedNCT01072669
22Stimulatory Autoantibodies to the Platelet-Derived Growth Factor Receptor (PDGFR) in Patients With Systemic SclerosisCompletedNCT00667134
23Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic SclerosisCompletedNCT01093885
24Digital UlcerationCompletedNCT01377090
25Treatment Study Comparing Medium or High Dose Uva-1 Treatment 3x/Week Versus Fluocinonide 0.05% Cream in the Treatment of Morphea.CompletedNCT00812188
26Botulinum Toxin in the Treatment of Raynaud'sCompletedNCT01233999
27Confirmation of Systemic Autoimmune Diseases in the Agricultural Health StudyCompletedNCT00341198
28The Effects of Exercise in Patients With Systemic SclerosisRecruitingNCT03058887
29Metabolomic Analysis of Systemic SclerosisActive, not recruitingNCT02298777
30Comparative Autoantibody and Immunologic Cell Marker StudyEnrolling by invitationNCT02422875
31Systemic Sclerosis Clinical and Biomarker StudyWithdrawnNCT02531009

Search NIH Clinical Center for Limited Scleroderma


Cochrane evidence based reviews: scleroderma, limited

Genetic Tests for Limited Scleroderma

About this section

Anatomical Context for Limited Scleroderma

About this section

MalaCards organs/tissues related to Limited Scleroderma:

36
Skin, Bone, Thyroid, T cells, Lung

Publications for Limited Scleroderma

About this section

Articles related to Limited Scleroderma:

(show all 38)
idTitleAuthorsYear
1
Successful long-term (22 Year) treatment ofA limited scleroderma using therapeutic plasma exchange: Is blood rheology theA key? (27340761)
2016
2
Systemic sclerosis - a multi-purpose use of ultrasound: Editorial comment on: G. PracoA8, M. PA8aza, M. Walentowska-Janowicz, I. SudoA8-SzopiA8ska The value of ultrasound in the diagnosis of limited scleroderma - a case report. (27104009)
2016
3
Upper gastrointestinal bleeding (watermelon stomach) in a patient with limited scleroderma (CREST syndrome). (27353193)
2016
4
Fibrillary glomerulonephritis associated with limited scleroderma: a case report. (26709524)
2016
5
The value of ultrasound in the diagnosis of limited scleroderma - a case report. (26675049)
2015
6
Osteonecrosis of Multiple Joints in a Patient With Limited Scleroderma/CREST Syndrome. (25807102)
2015
7
Pulsed versus continuous wave low-level light therapy on osteoarticular signs and symptoms in limited scleroderma (CREST syndrome): a case report. (25393970)
2014
8
Limited scleroderma with pauci-immune glomerulonephritis in the presence of renal cell carcinoma. (23656799)
2013
9
Improved survival in limited scleroderma-related pulmonary artery hypertension. (23361526)
2013
10
Increased prevalence of anti-thyroid antibodies in patients with limited scleroderma: comments on the article by Danielides et al. (22548259)
2012
11
Increased prevalence of anti-thyroid antibodies in patients with limited scleroderma. (21417550)
2011
12
Spontaneous pneumomediastinum in a patient with anti-centromere antibody-positive limited scleroderma. (21169848)
2011
13
Pneumatosis intestinalis in limited scleroderma. (18260164)
2008
14
Association of increased telomere lengths in limited scleroderma, with a lack of age-related telomere erosion. (18662931)
2008
15
Effects of olopatadine in limited scleroderma with peripheral eosinophils. (18822005)
2008
16
Clinically significant interstitial lung disease in limited scleroderma: histopathology, clinical features, and survival. (18403656)
2008
17
Lack of increased expression of cell surface markers for circulating fibrocyte progenitors in limited scleroderma. (17061153)
2007
18
Unilateral limited scleroderma-like changes following formation of an arteriovenous fistula. (17222301)
2007
19
Distinct recognition of antibodies to centromere proteins in primary Sjogren's syndrome compared with limited scleroderma. (16414973)
2006
20
Association of limited scleroderma and pulmonary hypertension in a patient with primary biliary cirrhosis. (16113494)
2005
21
Primary esophageal melanoma in a patient with limited scleroderma. (16357719)
2005
22
Calcinosis universalis in systemic sclerosis with limited scleroderma. (15789907)
2005
23
Pentoxyfilline treatment does not influence the plasma levels of IL-2 and sIL-2R in limited scleroderma patients. (11257736)
2001
24
Updating the American College of Rheumatology preliminary classification criteria for systemic sclerosis: addition of severe nailfold capillaroscopy abnormalities markedly increases the sensitivity for limited scleroderma. (11263791)
2001
25
Myasthenia gravis associated with limited scleroderma (CREST syndrome) (10701901)
2000
26
Antimitochondrial antibodies and their significance in diffuse and limited scleroderma. (19078387)
1999
27
Association of clonally expanded T cells with the syndrome of primary biliary cirrhosis and limited scleroderma. (10347101)
1999
28
Decreased nailfold capillary density in limited scleroderma with pulmonary hypertension. (9876945)
1998
29
Early assessment of pulmonary involvement in limited scleroderma. A case report. (10028872)
1998
30
Clinical images: Progressive calcifications and draining lesions following staphylococcal infection in a patient with limited scleroderma. (9485097)
1998
31
Exudative pleural effusion and pleural leukocytoclastic vasculitis in limited scleroderma. (9598909)
1998
32
Vasculitis and thrombotic thrombocytopenic purpura in a patient with limited scleroderma. (9058673)
1997
33
Diffuse blisters and erosions in a patient with limited scleroderma. Penicillamine-induced pemphigus foliaceus (PIPF). (9126027)
1997
34
Acute hemodynamic responses to inhaled nitric oxide in patients with limited scleroderma and isolated pulmonary hypertension. (8759092)
1996
35
Image interpretation session: 1995. Case 1. Exogenous lipoid pneumonia superimposed on systemic sclerosis with limited scleroderma (CREST syndrome). (10946703)
1996
36
Genetic and immunological differences between Japanese patients with diffuse scleroderma and limited scleroderma. (8151564)
1994
37
Elevated serum levels of soluble interleukin 2 receptor, interleukin 2 and neopterin in diffuse and limited scleroderma: effects of chlorambucil. (2213757)
1990
38
Development of severe limited scleroderma in complicated Raynaud's phenomenon after limb immobilization: report of two cases and study of collagen biosynthesis. (3753543)
1986

Variations for Limited Scleroderma

About this section

Expression for genes affiliated with Limited Scleroderma

About this section
Search GEO for disease gene expression data for Limited Scleroderma.

Pathways for genes affiliated with Limited Scleroderma

About this section

Pathways related to Limited Scleroderma according to GeneCards Suite gene sharing:

idSuper pathwaysScoreTop Affiliating Genes
1
Show member pathways
9.9HLA-DRB1, IL2, IL2RA
29.9HLA-DRB1, IL2, IL2RA
39.9CCR6, IL2, IL2RA
48.8ATRAID, IFI16, IL2, IL2RA, IRF5, MNDA

GO Terms for genes affiliated with Limited Scleroderma

About this section

Cellular components related to Limited Scleroderma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1condensed nuclear chromosome kinetochoreGO:000077810.3CENPA, CENPC
2condensed chromosome kinetochoreGO:00007779.9CENPA, CENPC, CENPS
3condensed nuclear chromosome, centromeric regionGO:00007809.9CENPA, CENPB, CENPC
4chromosome, centromeric regionGO:00007759.9CENPA, CENPB, CENPC, CENPS
5nuclear pericentric heterochromatinGO:00316189.7CENPA, CENPB, CENPC
6chromosomeGO:00056949.7CENPA, CENPB, CENPC, CENPS, TOP1

Biological processes related to Limited Scleroderma according to GeneCards Suite gene sharing:

(show all 8)
idNameGO IDScoreTop Affiliating Genes
1inflammatory response to antigenic stimulusGO:000243710.7HLA-DRB1, IL2RA
2negative regulation of lymphocyte proliferationGO:005067210.6IL2, IL2RA
3positive regulation of T cell differentiationGO:004558210.6IL2, IL2RA
4regulation of T cell homeostatic proliferationGO:004601310.6IL2, IL2RA
5CENP-A containing nucleosome assemblyGO:003408010.2CENPA, CENPC, CENPS
6kinetochore assemblyGO:005138210.1CENPA, CENPC, CENPS
7immune system processGO:00023769.9HLA-DRB1, IFI16, IL2, IL2RA, IRF5
8sister chromatid cohesionGO:00070629.6CENPA, CENPC, CENPS

Molecular functions related to Limited Scleroderma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1centromeric DNA bindingGO:001923710.8CENPB, CENPC
2chromatin bindingGO:00036829.8CENPA, CENPB, CENPS, TOP1, UBTF
3double-stranded DNA bindingGO:00036909.5CENPS, IFI16, TOP1
4DNA bindingGO:00036778.5CENPA, CENPB, CENPC, CENPS, IFI16, IRF5

Sources for Limited Scleroderma

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet